Drug Action
Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin- 1 beta receptor binding.
PDF page 911
Loading InternPractice…
Drug reference
Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin- 1 beta receptor binding.
PDF page 911
Gouty arthritis [in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or in those with contra-indications or intolerances to them, and in whom repeated courses of corticosteroids are inappropriate] ▶BY SUBCUTANEOUS INJECTION ▶Adult: 150 mg for 1 dose, in patients who respond, dose may be repeated after at least 12 weeks if symptoms recur, to be administered to the upper thigh, abdomen, upper arm or buttocks Cryopyrin-associated periodic syndromes (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight 41 kg and above): 150 mg every 8 weeks, to be administered to the upper thigh, abdomen, upper arm or buttocks, additional doses may be considered if clinical response not achieved within 7 days—consult product literature Tumour necrosis factor receptor associated periodic syndrome (specialist use only) | Hyperimmunoglobulin D syndrome (specialist use only) | Familial Mediterranean fever (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight 41 kg and above): 150 mg every 4 weeks, to be administered to the upper thigh, abdomen, upper arm or buttocks, a second dose may be considered if clinical response not achieved within 7 days—consult product literature Still’s disease (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 4 mg/kg every 4 weeks (max. per dose 300 mg), to be administered to the upper thigh, abdomen, upper arm or buttocks
PDF page 911
Active severe infection. leucopenia . neutropenia
PDF page 911
History of recurrent infection. latent and active tuberculosis. predisposition to infection CAUTIONS, FURTHER INFORMATION ▶Vaccinations Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk—consult product literature for further information.
PDF page 911
Patients should be evaluated for latent and active tuberculosis before starting treatment.
PDF page 911
→Appendix 1: monoclonal antibodies
PDF page 911
▶Common or very common Abdominal pain upper. arthralgia. asthenia. dizziness. increased risk of infection . leucopenia. neutropenia. pain. proteinuria. vertigo ▶Uncommon Gastrooesophageal reflux disease
PDF page 911
Effective contraception required during treatment and for up to 3 months after last dose.
PDF page 911
Manufacturer advises avoid unless potential benefit outweighs risk.
PDF page 911
Consider if benefit outweighs risk—not known if present in human milk.
PDF page 911
Limited information available but manufacturer advises no dose adjustment required.
PDF page 911
▶Manufacturer advises monitor full blood count including neutrophil count before starting treatment, 1–2 months Immune system and malignant disease after starting treatment, and periodically thereafter. ▶Manufacturer advises monitor for signs and symptoms of infection (including tuberculosis) during and after treatment. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8 °C).
PDF page 911
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Ilaris (Novartis Pharmaceuticals UK Ltd) Canakinumab 150 mg per 1 ml Ilaris 150mg/1ml solution for injection vials | 1 vial P £9,927.80 IMMUNOSUPPRESSANTS › MONOCLONAL ANTIBODIES › ANTI-LYMPHOCYTE
PDF page 911
Manufacturer advises patients and carers should be instructed to seek medical advice if signs or symptoms suggestive of tuberculosis (including persistent cough, weight loss and subfebrile temperature) occur. Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness and drowsiness.
PDF page 911
150 mg for 1 dose, in patients who respond, dose
First-line fragment. Read the complete Indications and Dose section above.
PDF page 911
150 mg every
First-line fragment. Read the complete Indications and Dose section above.
PDF page 911
150 mg every
First-line fragment. Read the complete Indications and Dose section above.
PDF page 911
4 mg/kg every 4 weeks (max. per dose 300 mg),
First-line fragment. Read the complete Indications and Dose section above.
PDF page 911